Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Blood (2025) 146 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2025-5830

Published: 2025

Journal Articles

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

Blood (2025) 146 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2025-5818

Published: 2025

Journal Articles

First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients

Fang Liu, Yu MA, Yecheng LI, Kevin G. Pinz, Xiao Wang, Masayuki Wada, Yupo Ma

Blood (2024) 144 (Supplement 1): 4842.

https://doi.org/10.1182/blood-2024-207626

Published: 2024

Journal Articles

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Fang Liu, MD PhD, Hongyu Zhang, MD PhD, Xiao Wang, MD PhD, Yisong Xiong, PhD, Yuanzhen Cao, Yi Su, MD, Hai Yi, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 38.

https://doi.org/10.1182/blood-2019-122964

Published: 2019

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

Fang Liu, MD PhD, Yuanzhen Cao, Kevin Pinz, Yu Ma, Masayuki Wada, PhD, Kevin Chen, Gina Ma, Jiaqi Shen, Charlotte Olivia Tse, Yi Su, MD, Yisong Xiong, PhD, Guangcui He, MD, Yecheng Li, MD, Yupo Ma, MD PhD

Blood (2018) 132 (Supplement 1): 901.

https://doi.org/10.1182/blood-2018-99-110579

Published: 2018

Journal Articles

Prognostic Factors and Survival Outcomes in Phase I Patients with Hematologic Malignancies

Matthew James Butler, MD, Josephine A Taverna, MD, Zuxi Cui, MS, Jiao Yu, MA, Joel E Michalek, PhD, Alex Bokov, PhD, Laura S Manuel, Amelie G Ramirez, DrPH, Alex V. Mejia, MD

Blood (2017) 130 (Supplement 1): 3452.

https://doi.org/10.1182/blood.V130.Suppl_1.3452.3452

Published: 2017

Journal Articles

Clinical Analysis of Invasive Fungal Infection after Allo-Geneic Stem Cell Transplantation

Ming Ni, MD, Baoan Chen, PhD Professor, Jia Hua Ding, PhD, Qiang Lin, Yu Ma

Blood (2015) 126 (23): 5487.

https://doi.org/10.1182/blood.V126.23.5487.5487

Published: 2015

Journal Articles

Psychometric Evaluation Of Health-Related Quality Of Life Assessments From The Along and Blong Hemophilia Clinical Trials

Kathleen W Wyrwich, PhD, Priscilla Auguste, MHS, Robyn von Maltzahn, MS, Ren Yu, MA, Sangeeta Krishnan, PharmD, MS, Nigel Dodd, MSc, Sylvia von Mackensen, PhD

Blood (2013) 122 (21): 423.

https://doi.org/10.1182/blood.V122.21.423.423

Published: 2013

Journal Articles

The Feature of MALT1-A20-NF-κB Expression Pattern Provide Important Insights Into the Therapeutic Benefit for T-ALL

Yu Ma, Xiuli Wu, Xu Wang, Fan Zhang, Lijian Yang, Shaohua Chen, Bo Li, Yangqiu Li

Blood (2012) 120 (21): 4810.

https://doi.org/10.1182/blood.V120.21.4810.4810

Published: 2012

Journal Articles

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Neil E. Kay, MD, Christopher R. Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Ian W. Flinn, MD, PhD, David Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, Susan Lerner, MS, Jeff Sharman, MD, Ren Yu, MA, Zeba M. Khan, PhD, Thomas K. Street, RPh, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, Chris L Pashos, PhD

Blood (2012) 120 (21): 3926.

https://doi.org/10.1182/blood.V120.21.3926.3926

Published: 2012

Journal Articles

Reliability and Validity of the FACT-AN In Patients with Low or Int-1-Risk Myelodysplastic Syndromes with Deletion 5q.

Nancy A Brandenburg, PhD, Ren Yu, MA, Dennis A Revicki, PhD

Blood (2010) 116 (21): 3827.

https://doi.org/10.1182/blood.V116.21.3827.3827

Published: 2010

Journal Articles

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Steven Buck, MS, Ron Yu, MA, Chitra Saraiya, MS, Lorrie Douglas, BS, Howard Weinstein, MD, Myron Chang, MD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Gary V. Dahl, MD, Branimir Sikic, MD, Yaddanapudi Ravindranath, MD

Blood (2004) 104 (11): 1130.

https://doi.org/10.1182/blood.V104.11.1130.1130

Published: 2004

Journal Articles

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Norman J. Lacayo, MD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Dennis J. Kuo, MD, Ron Yu, MA, Myron N. Chang, PhD, Cheryl L. Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir I. Sikic, MD, Howard Weinstein, MD, Gary V. Dahl, MD

Blood (2004) 104 (11): 570.

https://doi.org/10.1182/blood.V104.11.570.570

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study

Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study

First-in-Human Trial of BCMA-CD19 Compound CAR (cCAR) in Desensitization of Donor-Specific Anti-HLA Antibodies (DSAs) in Haploidentical Stem Cell Transplant Recipients

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

Prognostic Factors and Survival Outcomes in Phase I Patients with Hematologic Malignancies

Clinical Analysis of Invasive Fungal Infection after Allo-Geneic Stem Cell Transplantation

Psychometric Evaluation Of Health-Related Quality Of Life Assessments From The Along and Blong Hemophilia Clinical Trials

The Feature of MALT1-A20-NF-κB Expression Pattern Provide Important Insights Into the Therapeutic Benefit for T-ALL

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Reliability and Validity of the FACT-AN In Patients with Low or Int-1-Risk Myelodysplastic Syndromes with Deletion 5q.

Gene Expression Profiling Identifies Genes Associated with In Vitro Resistance to Daunorubicin and Cytarabine in Children with De Novo Acute Myelogenous Leukemia (AML) from the Pediatric Oncology Group (POG) Study # 9421.

FLT3 Mutations Determine the Clinical Outcome in Children with De Novo Acute Myelogenous Leukemia (AML) and Normal Karyotype: Pediatric Oncology Group (POG) Study # 9421.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only